Published in J Clin Microbiol on April 01, 2003
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals. J Clin Microbiol (2006) 2.52
Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol (2004) 1.73
What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J Clin Microbiol (2010) 1.70
Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. J Clin Microbiol (2008) 1.47
Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol (2003) 1.43
Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol (2009) 1.33
Multilocus variable-number tandem-repeat analysis and multilocus sequence typing reveal genetic relationships among Clostridium difficile isolates genotyped by restriction endonuclease analysis. J Clin Microbiol (2009) 1.21
Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis (2012) 1.09
Genetic relatedness of Clostridium difficile isolates from various origins determined by triple-locus sequence analysis based on toxin regulatory genes tcdC, tcdR, and cdtR. J Clin Microbiol (2008) 0.96
Clostridium difficile infection: molecular pathogenesis and novel therapeutics. Expert Rev Anti Infect Ther (2014) 0.92
Clonal spread of a Clostridium difficile strain with a complete set of toxin A, toxin B, and binary toxin genes among Polish patients with Clostridium difficile-associated diarrhea. J Clin Microbiol (2005) 0.87
Comparison of polymerase chain reaction ribotyping, toxinotyping and nutritional aspects of toxin production of Clostridium difficile strains. Biomed Rep (2014) 0.81
Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks. Emerg Microbes Infect (2016) 0.76
Clinical Characteristics and Treatment Outcomes of Clostridium difficile Infections by PCR Ribotype 017 and 018 Strains. PLoS One (2016) 0.75
Host immunity to Clostridium difficile PCR ribotype 017 strains. Infect Immun (2014) 0.75
Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model. Front Microbiol (2017) 0.75
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol (1998) 4.79
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol (1998) 3.34
Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol (1993) 2.94
Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med (2001) 2.72
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol (2000) 2.50
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Comparison of serogrouping and polyacrylamide gel electrophoresis for typing Clostridium difficile. J Clin Microbiol (1986) 2.43
Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem (1997) 2.25
Multicenter evaluation of the Clostridium difficile TOX A/B TEST. J Clin Microbiol (1998) 2.09
Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.07
Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology (2001) 2.04
Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile. J Clin Microbiol (2000) 1.91
Characterization of polymorphisms in the toxin A and B genes of Clostridium difficile. FEMS Microbiol Lett (1997) 1.88
Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Microbiol (2002) 1.83
Prevalence of toxin A negative/B positive Clostridium difficile strains. J Hosp Infect (1999) 1.80
Serogroup F strains of Clostridium difficile produce toxin B but not toxin A. J Med Microbiol (1993) 1.78
Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain. Eur J Clin Microbiol Infect Dis (2001) 1.71
Purification and characterisation of toxin B from a strain of Clostridium difficile that does not produce toxin A. J Med Microbiol (1991) 1.63
Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun (2000) 1.60
Genetic rearrangements in the pathogenicity locus of Clostridium difficile strain 8864--implications for transcription, expression and enzymatic activity of toxins A and B. Mol Gen Genet (1998) 1.49
Preliminary findings of the international typing study on Clostridium difficile. International Clostridium Difficile Study Group. Clin Infect Dis (1997) 1.37
Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR. J Clin Microbiol (2000) 1.28
Virulence of ten serogroups of Clostridium difficile in hamsters. J Med Microbiol (1990) 1.23
Clonal dissemination of a toxin-A-negative/toxin-B-positive Clostridium difficile strain from patients with antibiotic-associated diarrhea in Poland. Clin Microbiol Infect (2001) 1.20
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol (2010) 17.99
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
Burden of Clostridium difficile infection in the United States. N Engl J Med (2015) 8.17
Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol (2009) 7.89
Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med (2010) 7.37
Clostridium difficile infection in Europe: a hospital-based survey. Lancet (2011) 6.25
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol (1998) 4.79
Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol (2009) 3.66
A mouse model of Clostridium difficile-associated disease. Gastroenterology (2008) 3.65
Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis (2008) 3.32
Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology (2009) 3.29
Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis (2007) 3.15
Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 3.13
Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect (2007) 2.84
Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol (2000) 2.79
Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med (2013) 2.78
Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves, and other species. J Clin Microbiol (2007) 2.76
Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals. J Clin Microbiol (2006) 2.52
Comparison of serogrouping and polyacrylamide gel electrophoresis for typing Clostridium difficile. J Clin Microbiol (1986) 2.43
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother (2007) 2.43
A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.32
Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol (2010) 2.32
Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.30
Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol (2010) 2.29
Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 2.22
Clostridium difficile PCR ribotypes in calves, Canada. Emerg Infect Dis (2006) 2.12
Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis (2006) 1.99
Toxinotype V Clostridium difficile in humans and food animals. Emerg Infect Dis (2008) 1.98
Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis (2004) 1.98
A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis (2004) 1.96
Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis (2012) 1.96
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85
Strategies to prevent clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.84
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother (2008) 1.84
Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.81
Serogroup F strains of Clostridium difficile produce toxin B but not toxin A. J Med Microbiol (1993) 1.78
Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol (2004) 1.73
Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis (2002) 1.68
Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun (1994) 1.68
Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol (2008) 1.66
Comparison of strain typing results for Clostridium difficile isolates from North America. J Clin Microbiol (2011) 1.65
Distribution of nocardia species in clinical samples and their routine rapid identification in the laboratory. J Clin Microbiol (2005) 1.60
Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases. Clin Infect Dis (2004) 1.58
Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet (1987) 1.52
Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol (2004) 1.52
Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands. Infect Control Hosp Epidemiol (2010) 1.51
Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe (2009) 1.47
Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol (2003) 1.43
Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis (2012) 1.42
Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. Clin Infect Dis (2010) 1.41
lktA-encoded leukotoxin is not a universal virulence factor in invasive Fusobacterium necrophorum infections in animals and man. J Med Microbiol (2009) 1.41
Prevalence and association of PCR ribotypes of Clostridium difficile isolated from symptomatic patients from Warsaw with macrolide-lincosamide-streptogramin B (MLSB) type resistance. J Med Microbiol (2006) 1.39
Molecular epidemiology of Clostridium difficile over the course of 10 years in a tertiary care hospital. Clin Infect Dis (2009) 1.39
Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother (2011) 1.33
NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis (2014) 1.31
Genotyping of outbreak-related and sporadic isolates of Clostridium difficile belonging to serogroup C. J Clin Microbiol (1996) 1.31
Infection of hamsters with historical and epidemic BI types of Clostridium difficile. J Infect Dis (2007) 1.29
Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol (2005) 1.28
Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol (2008) 1.26
Characterization of flagella of Clostridium difficile and their role in serogrouping reactions. J Clin Microbiol (1990) 1.26
Clostridium difficile in neonates: serogrouping and epidemiology. Eur J Pediatr (1988) 1.25
Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother (1999) 1.23
Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother (2006) 1.23
Virulence of ten serogroups of Clostridium difficile in hamsters. J Med Microbiol (1990) 1.23
Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis (2005) 1.21
Multilocus variable-number tandem-repeat analysis and multilocus sequence typing reveal genetic relationships among Clostridium difficile isolates genotyped by restriction endonuclease analysis. J Clin Microbiol (2009) 1.21
New types of toxin A-negative, toxin B-positive strains among clinical isolates of Clostridium difficile in Australia. J Med Microbiol (2011) 1.18
Phenotypic and genotypic diversity of the flagellin gene (fliC) among Clostridium difficile isolates from different serogroups. J Clin Microbiol (2000) 1.18
Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile. Antimicrob Agents Chemother (1986) 1.18
Evaluation of Oxoid combination discs for detection of extended-spectrum beta-lactamases. J Antimicrob Chemother (2003) 1.17
Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe (2009) 1.15
Brevibacterium lutescens sp. nov., from human and environmental samples. Int J Syst Evol Microbiol (2003) 1.15
Difference in the incidence of Clostridium difficile among patients infected with human immunodeficiency virus admitted to a public hospital and a private hospital. Infect Control Hosp Epidemiol (2002) 1.15
Predominance of a single restriction endonuclease analysis group with intrahospital subgroup diversity among Clostridium difficile isolates at two Chicago hospitals. Infect Control Hosp Epidemiol (2002) 1.14
Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J Infect Dis (2003) 1.14
Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother (2012) 1.13
Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents. Eur J Epidemiol (1988) 1.12
Use of an enzyme-linked immunoassay for Clostridium difficile serogrouping. J Clin Microbiol (1993) 1.12
Epidemiology and prevention of Clostridium difficile infections in a leukemia unit. Eur J Clin Microbiol (1987) 1.11
Correlation between serogroup and susceptibility to chloramphenicol, clindamycin, erythromycin, rifampicin and tetracycline among 308 isolates of Clostridium difficile. J Antimicrob Chemother (1988) 1.07